Dr. Levine on Simulation in the Management of EGFR-Mutated Advanced NSCLC

Stacie Levine, MD
Published Online: Friday, Feb 10, 2017



Stacie Levine, MD, associate professor of Medicine, director, Geriatrics and Hospice and Palliative Medicine Fellowship Program, The University of Chicago Medicine, discusses a trial regarding simulation in the management of EGFR-mutated advanced non–small cell lung cancer (NSCLC).

Oncologists should be able to assess patients for the EGFR mutation and decide upon appropriate target therapies such as tyrosine kinase inhibitors (TKIs), regardless of the patient’s age, Levine explains.

The objective from this trial was to determine if simulation-based education that addresses clinical practice gaps could improve medical decision making for EGFR-mutated NSCLC.
 


Stacie Levine, MD, associate professor of Medicine, director, Geriatrics and Hospice and Palliative Medicine Fellowship Program, The University of Chicago Medicine, discusses a trial regarding simulation in the management of EGFR-mutated advanced non–small cell lung cancer (NSCLC).

Oncologists should be able to assess patients for the EGFR mutation and decide upon appropriate target therapies such as tyrosine kinase inhibitors (TKIs), regardless of the patient’s age, Levine explains.

The objective from this trial was to determine if simulation-based education that addresses clinical practice gaps could improve medical decision making for EGFR-mutated NSCLC.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Oncogenic Tumor Board in NSCLC: Targeting Driver Mutations to Maximize Therapeutic OutcomesAug 31, 20171.5
Community Practice Connections: Choosing Therapies for Patients with EGFR-Mutant Lung Cancers: More Options...More Decisions...Better OutcomesAug 31, 20172.0
Publication Bottom Border
Border Publication
$emailPop$